Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

Pfizer reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook as the drugmaker works to slash costs. The results come as Pfizer scrambles to ...

Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.

Analysts' ratings for Pfizer (NYSE:PFE) over the last quarter vary from bullish to bearish, as provided by 11 analysts. The table below provides a concise overview of recent ratings by analysts, ...

Pfizer PFE faces several near-term challenges like declining COVID sales, the upcoming loss of exclusivity (“LOE”) cliff and U.S. Medicare Part D headwinds. These headwinds can hurt its sales and ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...

Pfizer raised its full-year 2024 outlook after it reported higher-than-expected revenue in the first quarter of the year Wednesday morning. In its earnings report, the drugmaker said it brought in ...